MAR 19, 2020 7:32 AM PDT

Could a 1949 Malaria Drug Treat COVID-19?

WRITTEN BY: Annie Lennon

In the race to halt the current coronavirus pandemic, scientists, health experts and even Elon Musk are considering chloroquine, a drug that has been used against malaria since 1949, to be a potential treatment. 

Although there is as of yet no peer-reviewed clinical data showing that chloroquine is effective against COVID-19, early laboratory research and anecdotal reports on its usage provide encouraging evidence that it may be able to fight off the virus. 

This comes in particular after an expert consensus from the Department of Science and Technology of Guangdong Province, China and the Health Commission of Guangdong Province discussing the usage of the drug. In particular, they recommended dosage of chloroquine phosphate tablets, 500 mg twice daily for patients diagnosed with mild, moderate and severe cases of COVID-19 pneumonia. 

On top of this, a paper published by French researchers also indicated that chloroquine may be able to effectively fight against COVID-19. Given the wide availability of the drug, the researchers, led by Professor Didier Raoult of the IHU Méditerranée Infection in Marseille, France, wrote that, “If clinical data confirm the biological results, the novel coronavirus-associated disease will have become one of the simplest and cheapest to treat and prevent among infectious respiratory diseases."

For the paper, Raoult and his team conducted a non-randomized, unblinded study of 25 patients diagnosed with COVID-19. Although the data from the study is yet to be published, and thus should be taken with caution, the researchers say that after 6 days of treatment, the percentage of patients testing positive for COVID-19 treated with hydroxychloroquine fell by 75%, whereas for those who did not receive the treatment, just 10% of patients no longer tested positive. 

The study went on to say that for those given a combination of both hydroxychloroquine and antibiotic azithromycin, after six days, the percentage of cases still testing positive for COVID-19 fell to just 5%. According to Raoult, “Everyone who died from COVID-19 were still carriers of coronavirus. To no longer have the virus changes the prognosis.”

Although promising results, whether the drug may really be able to treat COVID-19 is still unknown until more data from ongoing clinical trials emerge from various sites around the world. 



Sources: PubMed, Tech Times, Science Direct and Medscape

About the Author
University College London
Annie Lennon is a writer whose work also appears in Medical News Today, Psych Central, Psychology Today, and other outlets. When she's not writing, she is COO of Xeurix, an HR startup that assesses jobfit from gamified workplace simulations.
You May Also Like
MAY 19, 2022
Neuroscience
The Unconscious Brain at Work
MAY 19, 2022
The Unconscious Brain at Work
A study published in Neuron revealed how different cell types in the cerebral cortex change their activity during genera ...
MAY 25, 2022
Neuroscience
The Connection Between Bizarre Dreams and Deeper Learning
MAY 25, 2022
The Connection Between Bizarre Dreams and Deeper Learning
A study published in eLife found that wakefulness, non-REM, and REM sleep have complementary functions for learning. Uni ...
JUN 02, 2022
Cancer
Call to Diversify Clinical Trials
JUN 02, 2022
Call to Diversify Clinical Trials
Clinical Trials represent an integral component of biomedical research.  These research studies utilize human subje ...
JUN 06, 2022
Drug Discovery & Development
Weight loss Surgery Reduces Cancer Risk and Cancer Deaths
JUN 06, 2022
Weight loss Surgery Reduces Cancer Risk and Cancer Deaths
Weight loss achieved via bariatric surgery among adults with obesity is linked to a lower risk of developing cancer and ...
JUN 10, 2022
Cannabis Sciences
Are Cannabis Users Nicer?
JUN 10, 2022
Are Cannabis Users Nicer?
A study published in Nature offers evidence that cannabis has a positive effect on the psychosocial health of young adul ...
JUN 19, 2022
Drug Discovery & Development
Oral Immunotherapy for Peanut Allergy Most Effective Before 12 Months Old
JUN 19, 2022
Oral Immunotherapy for Peanut Allergy Most Effective Before 12 Months Old
Oral immunotherapy for peanut allergies is safer and more effective in children under 12 months old than in toddlers and ...
Loading Comments...